An Open-label, Multi-centre, Expanded Treatment Protocol of Oral Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed, and Relapsed and Refractory Multiple Myeloma
The purpose of this study is to provide oral panobinostat (PAN) treatment to relapsed or
relapsed and refractory multiple myeloma patients who are without satisfactory treatment
alternatives prior to the commercial availability* and reimbursement of panobinostat during
the regulatory approval process. This protocol will acquire additional safety data on the
use of panobinostat in combination with bortezomib (BTZ) and dexamethasone (Dex) in patients
with relapsed or relapsed and refractory multiple myeloma. In this protocol, PAN must be
administered in the defined regimen in combination with both BTZ and DEX.
*(Note: throughout this protocol "commercially available" means local health authority
approval and a functional method for reimbursement)
This is an open-label, single arm, multi-centre study of oral panobinostat administered in
combination with bortezomib and dexamethasone in patients with relapsed, and relapsed and
refractory multiple myeloma.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society